The efficacies of these new PKD inhibitors for chronic inflammatory diseases where the TLR/IL-1R pathway contributes to the pathogenesis, including RA, might be interesting enough to evaluate in the near future. This evidence concerns the gene IL1R1 and rheumatoid arthritis.